novel TT combinations
hetero-combinations
effective combinations
Homo-combinations
drug combinations able
combinations of interceptors able
long awaited application of TT combinations
evidence-based combinations of approved
mechanisms of drug action
mechanisms of action
driven resistance
lung cancer models
PKIs
immune system
novel cancer drugs Background
immune effectors
immune receptors
specific drugs
TT harness poly-pharmacology
monoclonal antibodies
cocktails of drugs
mAbs
deeper understanding of mechanisms
distinct signalling
distinct epitopes
selected interceptors
addictions of tumours
specific aims
animal models
major cause of oncology related fatalities
Molecular targeted therapy
protein kinase inhibitors
intercepts oncogene
mutant EGFR
interactions
myeloid cells
High granularity maps of compensatory loops
RNA interference
senescence
apoptosis
HER2
driver mutations
mapping adaptations
bases
potential synergies
interface
immunological cytotoxicity
Detailed knowledge of adaptation
hypothesis
MET
primary target
Phosphoproteomics
transcriptomics
disease
AXL
route
Goal
opportunities
limited toxicities
chemotherapy
Significance
monotherapies